Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ...
Cash Balance: CHF2.8 million as of March 31, 2025.
Cash Runway: Expected to last through mid-2026.
Continuing R&D Expenses: CHF0.1 million, primarily related to the GABAB PAM program.
Continuing G&A Expenses: CHF0.5 million, primarily related to corporate loan activities.
Net Loss from Discontinued Operations: Specific line item due to divested business.
Current Liabilities: CHF1.1 million as of March 31, 2025.
Non-Current Liabilities: CHF0.1 million as of March 31, 2025.
Equity Interest: 20% equity interest in a divested business, recorded under non-current assets.
Warning! GuruFocus has detected 6 Warning Signs with ADXN.
Release Date: June 19, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Addex Therapeutics Ltd (NASDAQ:ADXN) has made significant progress in its GABAB positive allosteric modulator program with partner Indivior, completing IND-enabling studies for substance use disorders.
The company regained rights to its mGluR2 positive allosteric modulator program from Johnson & Johnson, opening new therapeutic opportunities.
Addex Therapeutics Ltd (NASDAQ:ADXN) has repositioned its mGluR5 negative allosteric modulator program for brain injury recovery, with promising preclinical data supporting its potential.
The company has a strong cash position with CHF2.8 million, providing a runway through mid-2026, and has reduced cash burn following the Neurosterix spinout.
Addex Therapeutics Ltd (NASDAQ:ADXN) has a robust pipeline with multiple programs advancing, including a promising candidate for chronic cough with favorable preclinical efficacy and tolerability.
The current cash position does not fund the progression of unpartnered programs into the clinic, indicating potential future financing needs.
Revenue decreased compared to the previous year due to the completion of the funded research phase with Indivior, impacting financial performance.
The company faces competition in the chronic cough market, with existing compounds showing promising efficacy but challenging tolerability profiles.
There is uncertainty regarding the clinical development pathway and competitive landscape for the chronic cough program, which could impact future success.
Addex Therapeutics Ltd (NASDAQ:ADXN) needs to conduct further studies to optimize the use of dipraglurant in post-stroke rehabilitation, indicating a longer timeline before potential market entry.
Q: Can you provide your updated thoughts on the current competitive landscape in chronic cough and the relevance of proceeding programs for your clinical development pathway? A: Mikhail Kalinichev, Head of Translational Science, explained that there are several compounds in development, such as now roofing, which has shown promising efficacy but with tolerability challenges. Addex aims to deliver similar efficacy with improved tolerability, targeting both IPF-related and refractory chronic cough. The development plan includes studies in healthy volunteers and a challenge study in chronic cough patients, followed by a Phase 2 study with advanced monitoring technologies.
Q: Can you comment on the potential applicability of your agent for chronic painful cough in indications outside of IPF, like pulmonary sarcoidosis? A: Mikhail Kalinichev noted that chronic painful cough could be a suitable indication due to the sustained activation of GABAB across multiple conditions, including chronic cough. Tim Dyer, CEO, added that they are considering this indication for Phase 2 development.
Q: Regarding dipraglurant in post-stroke rehabilitation, what would an appropriate control arm look like in a registration-quality study, and what is the efficacy bar in this indication? A: Mikhail Kalinichev stated that dipraglurant would be used alongside physiotherapy due to its short half-life and good tolerability. They plan to conduct clinical pharmacology studies to understand its modulation effects better, which will inform the design of a Phase 2 study. The efficacy bar is challenging as no pharmacotherapies are currently approved in this context.
Q: Can you elaborate on the strategic importance of your GABAB positive allosteric modulator program with Indivior? A: Tim Dyer highlighted the program's potential to deliver a better baclofen for substance use disorders, with a longer half-life and improved side effect profile. The partnership with Indivior is crucial, as it allows Addex to advance its own independent GABAB PAM program for chronic cough, leveraging the strong rationale for GABAB PAMs in this area.
Q: What are the financial implications of your recent achievements and strategic partnerships? A: Tim Dyer reported that Addex completed Q1 2025 with CHF2.8 million in cash, providing a runway through mid-2026. The cash burn has been reduced following the Neurosterix spinout, and the company is well-positioned to deliver on strategic objectives, including advancing their pipeline and exploring new partnerships.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
15 minutes ago
- Bloomberg
Switzerland Follows European Union in Lifting Sanctions on Syria
Switzerland is lifting economic sanctions on Syria, following an European Union decision to the same end.
Fast Company
17 minutes ago
- Fast Company
How this Parisian music streaming service is fighting AI fraud
Music streaming service Deezer said Friday that it will start flagging albums with AI-generated songs, part of its fight against streaming fraudsters. Deezer, based in Paris, is grappling with a surge in music on its platform created using artificial intelligence tools it says are being wielded to earn royalties fraudulently. The app will display an on-screen label warning about 'AI-generated content' and notify listeners that some tracks on an album were created with song generators. Deezer is a small player in music streaming, which is dominated by Spotify, Amazon and Apple, but the company said AI-generated music is an 'industry-wide issue.' It's committed to 'safeguarding the rights of artists and songwriters at a time where copyright law is being put into question in favor of training AI models,' CEO Alexis Lanternier said in a press release. Deezer's move underscores the disruption caused by generative AI systems, which are trained on the contents of the internet including text, images and audio available online. AI companies are facing a slew of lawsuits challenging their practice of scraping the web for such training data without paying for it. According to an AI song detection tool that Deezer rolled out this year, 18% of songs uploaded to its platform each day, or about 20,000 tracks, are now completely AI generated. Just three months earlier, that number was 10%, Lanternier said in a recent interview. AI has many benefits but it also 'creates a lot of questions' for the music industry, Lanternier told the Associated Press. Using AI to make music is fine as long as there's an artist behind it but the problem arises when anyone, or even a bot, can use it to make music, he said. Music fraudsters 'create tons of songs. They upload, they try to get on playlists or recommendations, and as a result they gather royalties,' he said. Musicians can't upload music directly to Deezer or rival platforms like Spotify or Apple Music. Music labels or digital distribution platforms can do it for artists they have contracts with, while anyone else can use a 'self service' distribution company. Fully AI-generated music still accounts for only about 0.5% of total streams on Deezer. But the company said it's 'evident' that fraud is 'the primary purpose' for these songs because it suspects that as many as seven in 10 listens of an AI song are done by streaming 'farms' or bots, instead of humans. Any AI songs used for 'stream manipulation' will be cut off from royalty payments, Deezer said. AI has been a hot topic in the music industry, with debates swirling around its creative possibilities as well as concerns about its legality. Two of the most popular AI song generators, Suno and Udio, are being sued by record companies for copyright infringement, and face allegations they exploited recorded works of artists from Chuck Berry to Mariah Carey. Gema, a German royalty-collection group, is suing Suno in a similar case filed in Munich, accusing the service of generating songs that are 'confusingly similar' to original versions by artists it represents, including 'Forever Young' by Alphaville, 'Daddy Cool' by Boney M and Lou Bega's 'Mambo No. 5.' Major record labels are reportedly negotiating with Suno and Udio for compensation, according to news reports earlier this month. To detect songs for tagging, Lanternier says Deezer uses the same generators used to create songs to analyze their output. 'We identify patterns because the song creates such a complex signal. There is lots of information in the song,' Lanternier said. The AI music generators seem to be unable to produce songs without subtle but recognizable patterns, which change constantly. 'So you have to update your tool every day,' Lanternier said. 'So we keep generating songs to learn, to teach our algorithm. So we're fighting AI with AI.' Fraudsters can earn big money through streaming. Lanternier pointed to a criminal case last year in the U.S., which authorities said was the first ever involving artificially inflated music streaming. Prosecutors charged a man with wire fraud conspiracy, accusing him of generating hundreds of thousands of AI songs and using bots to automatically stream them billions of times, earning at least $10 million.
Bloomberg
25 minutes ago
- Bloomberg
French Lawmakers Urged to Drop Moratorium on Renewable Projects
France's renewable energy industry urged lawmakers to ditch proposed legislation that would impose a moratorium on approving new solar and wind projects, saying it would destroy jobs and stall the nation's plan to curb its use of polluting fossil fuels. The outcry comes as lawmakers of Marine Le Pen's anti-immigration party and some conservative legislators amended a proposed energy bill on Thursday with the moratorium, blaming solar and wind for boosting energy prices. The legislation, which also calls for the construction of new atomic plants, will be submitted to a vote in the Lower House of Parliament on June 24, and — if adopted — will be sent back to the Senate for a second reading.
